柳药集团 (603368.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	21.0B	20.9B	21.2B	20.8B	19.1B
Cost of Revenue	18.7B	18.6B	18.8B	18.3B	16.9B
Gross Profit	2.3B	2.3B	2.4B	2.5B	2.2B
Operating Expenses
R&D Expense	41.7M	38.5M	39.6M	36.6M	25.8M
SG&A Expense	—	—	—	—	—
General & Admin Expense	403.3M	403.8M	423.9M	470.4M	416.6M
Selling & Marketing Expense	698.1M	678.4M	629.7M	553.8M	533.8M
Other Expenses	—	—	—	—	—
Total Operating Expenses	1.4B	1.4B	1.4B	1.4B	1.3B
Cost and Expenses	20.1B	20.0B	20.2B	19.7B	18.1B
Operating Income (EBIT)	848.2M	882.4M	1.0B	1.0B	890.1M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	832.5M	869.9M	1.0B	1.0B	890.4M
Income Tax Expense	164.2M	149.4M	135.6M	136.8M	131.4M
Bottom Line
Net Income	656.7M	709.5M	854.9M	849.6M	701.5M
Earnings from Cont. Ops	668.3M	720.5M	867.5M	906.6M	759.0M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	656.7M	709.5M	854.9M	849.6M	701.5M
Per Share
Basic EPS	CN¥1.73	CN¥1.79	CN¥2.21	CN¥2.35	CN¥1.94
Diluted EPS	CN¥1.73	CN¥1.79	CN¥2.21	CN¥2.35	CN¥1.94
Revenue Per Share	CN¥59.81	CN¥52.80	CN¥54.76	CN¥57.57	CN¥52.69
Shares
Basic Shares Outstanding	350.9M	396.3M	386.8M	361.5M	361.6M
Diluted Shares Outstanding	350.9M	396.3M	386.8M	361.5M	361.6M
Profitability Metrics
EBITDA	—	1.0B	1.1B	1.2B	1.0B
D&A	—	123.0M	130.5M	130.8M	133.8M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026